Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Jubilant Life Sciences Ltd (JUBILANT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9847
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical ingredients (APIs), solid dosage formulations, life science chemicals, nutritional products, fine ingredients, advance intermediates and crop science ingredients. It also provides contract manufacturing of sterile injectables and drug discovery and development services. The company caters its products and services to customers across India, North America, Canada, Europe and China. It owns and operates cGMP compliant manufacturing facilities, and research and development centers in India, the US and Canada. Jubilant is headquartered in Noida, Uttar Pradesh, India.

Jubilant Life Sciences Ltd (JUBILANT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Partnerships 15
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Licensing Agreements 20
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Equity Offering 22
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Debt Offering 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Asset Transactions 29
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Acquisition 30
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd – Key Competitors 33
Jubilant Life Sciences Ltd – Key Employees 34
Jubilant Life Sciences Ltd – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 38
Financial Announcements 38
Oct 22, 2018: Jubilant Life Sciences: Q2 & H1 ‘FY19 Results 38
Jul 27, 2018: Jubilant Life Sciences- Q1 FY 2019 Results – Jubilant Reports Strong Performance in Q1’FY19 Revenue at Rs. 2,079 Crore, up 34% YoY 42
May 09, 2018: Jubilant Life Sciences – Q4/ FY2018 Results- Jubilant Reports Strong Performance in Q4’FY18 Revenue at Rs. 2,252 crore, up 41% YOY; EBITDA at Rs. 481 crore, up 52% YOY PAT at Rs 155 crore 45
Jan 17, 2018: Jubilant Reports Record Performance In Q3 FY2018; Highest Ever Revenues And Profits Revenue At Rs. 2,068 Crore, Up 42% YOY and Ebitda at Rs. 431 Crore, Up 28% YOY Pat At Rs. 213 Crore, Up 78% YOY With 49
Oct 28, 2017: Jubilant Life Sciences: Q2/H1 FY2018 Results 53
Jul 18, 2017: Jubilant Life Sciences: Q1 FY2018 Result 57
Jul 18, 2017: Jubilant Reports Q1 FY2018 Revenue of Rs. 1,596 Crore, UP 10% YOY Pharma Segment Records Highest Ever Sales Ebitda of Rs. 344 Crore and Margins of 21.6%; Pat of Rs. 147 Crore 59
May 23, 2017: Jubilant Life Sciences Reports Total RevenueOf INR26.2 Billion In Fiscal 2017 61
Feb 07, 2017: Jubilant Reports Strong Performance In Q3 FY17; Sales At Rs. 1,492 Crore, Up By 7% YOY EBITDA At Rs. 337 Crore; Up 9% YOY With Margins Of 22.6%; PAT At Rs. 120 Crore 62
Corporate Communications 65
Oct 22, 2018: Jubilant Life Sciences announces appointment of directors 65
Jan 17, 2018: Jubilant Life Sciences: Changes in the Board of Directors 66
Legal and Regulatory 67
Mar 04, 2018: Jubilant Life Sciences: Commissioner of State Excise Cancelled License DS-1 License and Form-I License relating to the Distillery operations 67
Jan 25, 2017: Jubilant Life Sciences is now Responsible Care 14001: 2013 certified 68
Other Significant Developments 69
Jun 01, 2017: Jubilant Life Sciences Provides Update on Gajraula Manufacturing Unit 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Jubilant Pharma Plans to Acquire Pharma Business in US 14
Jubilant Biosys Enters into Agreement with Sanofi-Aventis Deutschland 15
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 16
Jubilant Chemsys Enters into Research Agreement with Infectious Disease Research Institute 17
Motif BioSciences Enters Into Co-Development Agreement With Jubilant Biosys 18
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 19
Checkpoint Therapeutics Amends its Licensing Agreement with Jubilant Biosys 20
TG Therapeutics Amends its Licensing Agreement with Jubilant Biosys 21
Jubilant Pharma Plans to Raise up to USD700 Million in IPO of Shares 22
Jubilant Life Sciences Raises USD14 Million in Private Placement of 9.1% Debentures Due 2021 23
Jubilant Life Sciences Raises USD14 Million in Private Placement of 8.95% Debentures Due 2020 24
Jubilant Life Sciences Raises USD21 Million in Private Placement of 9.26% Debentures Due 2022 25
Jubilant Life Sciences Raises USD72.6 Million in Private Placement of Debentures 26
Jubilant Pharma Raises USD300 Million in Private Placement of 4.875% Bonds Due 2021 27
Jubilant Life Sciences Plans Debt Offering For US$250 Million 28
Narayana Health Acquires Hospital Business From Jubilant First Trust Healthcare 29
Drug Discovery and Development Solutions to Acquire Jubilant Discovery Services for USD2.9 Million 30
General Atlantic Divests its 6% Stake in Jubilant Life Sciences for USD2.2 Million 31
Jubilant Acquires Remaining 17.6% Stake in Cadista for up to USD33.2 Million in Tender Offer 32
Jubilant Life Sciences Ltd, Key Competitors 33
Jubilant Life Sciences Ltd, Key Employees 34
Jubilant Life Sciences Ltd, Other Locations 35
Jubilant Life Sciences Ltd, Subsidiaries 35

List of Figures
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Jubilant Life Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Jubilant Life Sciences Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lidco Group Plc (LID):企業の財務・戦略的SWOT分析
    Summary Lidco Group Plc (LiDCO) is a medical device company that supplies hemodynamic monitoring equipment. The company offers products such as LiDCOrapid, LiDCOunity, LiDCOplus, LiDCOview and LiDCOaccessories . Its LiDCOplus is a computer-based platform monitor, which is used in the intensive care …
  • PSA Peugeot Citroen S.A. (PSA Groupe):戦略・SWOT・企業財務分析
    PSA Peugeot Citroen S.A. (PSA Groupe) - Strategy, SWOT and Corporate Finance Report Summary PSA Peugeot Citroen S.A. (PSA Groupe) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Japan Foods Co Ltd:企業の戦略・SWOT・財務情報
    Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Japan Foods Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • One Lambda Inc:医療機器:M&Aディール及び事業提携情報
    Summary One Lambda Inc (One Lambda), a subsidiary of Thermo Fisher Scientific Inc is a medical device manufacturing company that offers laboratory products. The company develops and distributes antibody detection products and histocompatibility typing tests. Its products include HLA testing reagents …
  • Otsuka Corp (4768):企業の財務・戦略的SWOT分析
    Otsuka Corp (4768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Porton Fine Chemicals Ltd (300363):製薬・医療:M&Aディール及び事業提携情報
    Summary Porton Fine Chemicals Ltd (Porton) is a supplier of custom drug intermediates and active pharmaceutical ingredients. The company provides custom and contract chemical development, and contract manufacturing services. It provides products such as reactive reagents, chiral chromatography produ …
  • Translate Bio Inc (TBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc is a healthcare service provider that develops therapies which targets RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • EarLens Corp:医療機器:M&Aディール及び事業提携情報
    Summary EarLens Corp (EarLens) is engaged in designing and manufacturing of hearing aid products for hearing impaired patients. Its lead product Earlens Hearing Aid is a hearing device that utilizes light to transmit sound. The device automatically adjusts to noisy environments and delivers the broa …
  • Deloitte Touche Tohmatsu Limited:企業の戦略・SWOT・財務分析
    Deloitte Touche Tohmatsu Limited - Strategy, SWOT and Corporate Finance Report Summary Deloitte Touche Tohmatsu Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Petroleum, Oil and Gas Corporation of South Africa (SOC) Ltd-石油・ガス分野:企業M&A・提携分析
    Summary Petroleum, Oil and Gas Corporation of South Africa (SOC) Ltd (PetroSA) a subsidiary of CEF SOC Limited, is an integrated oil and gas company. It explores and produces oil and natural gas resources. The company operates Jubilee, Oribi, and Oryx oil fields; F-A and F-A Satellite, E-M and E-M S …
  • Greencore Group Plc:企業のM&A・事業提携・投資動向
    Greencore Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Greencore Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Arcadia Group Limited:企業の戦略・SWOT・財務情報
    Arcadia Group Limited - Strategy, SWOT and Corporate Finance Report Summary Arcadia Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Dexia Group:企業のM&A・事業提携・投資動向
    Dexia Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dexia Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Medical Developments International Ltd (MVP):企業の財務・戦略的SWOT分析
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • Grafton Group Plc:企業の戦略・SWOT・財務情報
    Grafton Group Plc - Strategy, SWOT and Corporate Finance Report Summary Grafton Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • ImmunoGen, Inc.:企業のM&A・事業提携・投資動向
    ImmunoGen, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ImmunoGen, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Bet Shemesh Engines Holdings (1997) Ltd
    Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report Summary Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Australian Securities & Investments Commission:企業の戦略的SWOT分析
    Australian Securities & Investments Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆